CL2008001667A1 - Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño. - Google Patents
Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño.Info
- Publication number
- CL2008001667A1 CL2008001667A1 CL2008001667A CL2008001667A CL2008001667A1 CL 2008001667 A1 CL2008001667 A1 CL 2008001667A1 CL 2008001667 A CL2008001667 A CL 2008001667A CL 2008001667 A CL2008001667 A CL 2008001667A CL 2008001667 A1 CL2008001667 A1 CL 2008001667A1
- Authority
- CL
- Chile
- Prior art keywords
- neurological
- trauma
- pain
- depression
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
COMPUESTOS DE FÓRMULA I:<br /> EN DONDE R1 Y Q SON COMO SE DESCRIBEN EN LA MEMORIA DESCRIPTIVA Y PLIEGO, SUS SALES FARMACÉUTICAMENTE<br /> ACEPTABLES, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO PARA EL TRATAMIENTO DE TRASTORNOS<br /> NEUROLÓGICOS Y PSIQUIÁTRICOS TALES COMO ISQUEMIA CEREBRAL, TRAUMA EN LA MÉDULA ESPINAL, DOLOR, DEPRESIÓN<br /> Y TRASTORNOS DEL SUEÑO.<br />
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94255307P | 2007-06-07 | 2007-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001667A1 true CL2008001667A1 (es) | 2009-03-06 |
Family
ID=40093925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001667A CL2008001667A1 (es) | 2007-06-07 | 2008-06-06 | Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño. |
Country Status (34)
Country | Link |
---|---|
US (2) | US8377940B2 (es) |
EP (2) | EP2444399B1 (es) |
JP (2) | JP5416696B2 (es) |
KR (2) | KR20100017640A (es) |
CN (2) | CN102977086B (es) |
AR (1) | AR066882A1 (es) |
AU (1) | AU2008260717B2 (es) |
BR (1) | BRPI0812889A2 (es) |
CA (1) | CA2690856C (es) |
CL (1) | CL2008001667A1 (es) |
CO (1) | CO6251287A2 (es) |
CY (2) | CY1113422T1 (es) |
DK (2) | DK2444399T3 (es) |
EC (1) | ECSP109856A (es) |
ES (2) | ES2531443T3 (es) |
HK (2) | HK1142318A1 (es) |
HR (2) | HRP20120909T4 (es) |
IL (1) | IL202158A (es) |
ME (1) | ME01488B (es) |
MX (1) | MX2009013078A (es) |
MY (1) | MY158066A (es) |
NZ (1) | NZ582445A (es) |
PE (1) | PE20090328A1 (es) |
PL (2) | PL2444399T3 (es) |
PT (2) | PT2444399E (es) |
RS (2) | RS53845B1 (es) |
RU (2) | RU2470931C2 (es) |
SA (1) | SA08290344B1 (es) |
SI (2) | SI2444399T1 (es) |
TW (1) | TWI417100B (es) |
UA (1) | UA99129C2 (es) |
UY (1) | UY31124A1 (es) |
WO (1) | WO2008150233A1 (es) |
ZA (1) | ZA200908285B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7807706B2 (en) * | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
US7868008B2 (en) * | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
TW200804281A (en) * | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途 |
TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
CA2698929C (en) | 2007-09-14 | 2016-01-19 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones |
CN101848893B (zh) | 2007-09-14 | 2012-06-06 | 奥梅-杨森制药有限公司 | 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮 |
MX2010005110A (es) * | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
US7790760B2 (en) * | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
NZ590616A (en) | 2008-06-20 | 2012-09-28 | Astrazeneca Ab | Dibenzothiazepine derivatives and use thereof |
JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体 |
EP2346505B1 (en) | 2008-10-16 | 2014-04-23 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
MX2011011964A (es) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
AU2010246607B2 (en) | 2009-05-12 | 2012-09-27 | Addex Pharma S.A. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
SG181958A1 (en) | 2010-01-07 | 2012-07-30 | Astrazeneca Ab | Process for making a metabotropic glutamate receptor positive allosteric modulator - 874 |
KR20130094179A (ko) * | 2010-04-30 | 2013-08-23 | 아스트라제네카 아베 | 대사형 글루탐산 수용체 양성 알로스테릭 조정자의 다형체 |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
WO2012062759A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
CN102180872B (zh) * | 2011-04-01 | 2014-04-02 | 华中科技大学 | [1,3,4]噁二唑类衍生物及其应用 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
EA033889B1 (ru) | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа |
CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
EP3327019A4 (en) * | 2015-07-17 | 2019-04-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC CONNECTION |
EP3342772A4 (en) | 2015-08-25 | 2019-03-27 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2021009355A1 (en) * | 2019-07-18 | 2021-01-21 | Abaxys Therapeutics | Solid formulation of a 1,2,4-oxadiazole derivative |
GB2621323A (en) | 2022-08-03 | 2024-02-14 | Sirgartan Holdings Ltd | Treatments for obsessive compulsive disorder |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2008803A (en) * | 1932-04-18 | 1935-07-23 | Stephan Engineering Corp | Fuel atomizing and igniting means |
US3993617A (en) * | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
US5175157A (en) * | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
WO1992017448A1 (en) | 1991-04-01 | 1992-10-15 | Kyowa Hakko Kogyo Co., Ltd. | 3-methyleneisoindolin-1-one derivative |
TW219935B (es) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
EP0602814A1 (en) | 1992-12-18 | 1994-06-22 | Takeda Chemical Industries, Ltd. | Crystal forms of optically active isoindolines and their use |
RU2124511C1 (ru) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Производные пиперазина |
US5681954A (en) * | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
WO1997029079A1 (fr) * | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Composes chimiques et utilisation pharmaceutique |
CA2291630A1 (en) | 1997-05-30 | 1998-12-03 | Tetsutaro Niizato | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same |
IL136250A0 (en) | 1997-11-21 | 2001-05-20 | Nps Pharma Inc | Metabotropic glutamate receptor antagonist compounds |
ATE366249T1 (de) * | 2000-02-29 | 2007-07-15 | Mitsubishi Pharma Corp | Zyklische amid-derivate |
HUP0302966A2 (hu) | 2000-07-31 | 2003-12-29 | Smithkline Beecham P.L.C. | Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
WO2002088092A1 (fr) * | 2001-04-19 | 2002-11-07 | Eisai Co., Ltd. | Derive de 2-imino-imidazole (2) |
HUP0401963A3 (en) | 2001-08-09 | 2006-01-30 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
AU2003226927A1 (en) | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
GB0223232D0 (en) | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
AU2003284669B2 (en) * | 2002-11-26 | 2009-11-12 | Maruishi Pharmaceutical Co., Ltd. | Isoindoline derivative |
EP1611096A4 (en) | 2003-03-26 | 2007-08-29 | Merck & Co Inc | BENZAMIDE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
GB0308025D0 (en) | 2003-04-07 | 2003-05-14 | Glaxo Group Ltd | Compounds |
US7129260B2 (en) * | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
JP2007510629A (ja) | 2003-10-22 | 2007-04-26 | イーライ リリー アンド カンパニー | 新規mch受容体アンタゴニスト |
EP1713775A4 (en) | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
ATE402935T1 (de) * | 2004-02-18 | 2008-08-15 | Astrazeneca Ab | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen |
CN102558082B (zh) | 2004-03-05 | 2015-09-30 | 日产化学工业株式会社 | 异噁唑啉取代苯甲酰胺化合物的制备中间体 |
CN1934094A (zh) | 2004-03-05 | 2007-03-21 | 万有制药株式会社 | 二芳基取代杂环5元环衍生物 |
SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
JP2008517920A (ja) | 2004-10-25 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体の複素環式インダノン増強因子 |
CA2598531A1 (en) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
NZ564254A (en) * | 2005-05-18 | 2011-04-29 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
TW200728277A (en) | 2005-06-29 | 2007-08-01 | Palau Pharma Sa | Bicyclic derivatives as P38 inhibitors |
JP2009509921A (ja) * | 2005-08-12 | 2009-03-12 | アストラゼネカ アクチボラグ | 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用 |
US7807706B2 (en) * | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
US7868008B2 (en) * | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
BRPI0616571A2 (pt) * | 2005-09-27 | 2011-06-21 | Hoffmann La Roche | oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo |
TW200804281A (en) | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途 |
TW200911255A (en) * | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
-
2008
- 2008-06-04 TW TW097120762A patent/TWI417100B/zh not_active IP Right Cessation
- 2008-06-05 KR KR1020097025404A patent/KR20100017640A/ko active Search and Examination
- 2008-06-05 RU RU2009147708/04A patent/RU2470931C2/ru not_active IP Right Cessation
- 2008-06-05 RS RS20150130A patent/RS53845B1/en unknown
- 2008-06-05 US US12/663,371 patent/US8377940B2/en not_active Expired - Fee Related
- 2008-06-05 NZ NZ582445A patent/NZ582445A/en not_active IP Right Cessation
- 2008-06-05 SI SI200831385T patent/SI2444399T1/sl unknown
- 2008-06-05 MY MYPI20095187A patent/MY158066A/en unknown
- 2008-06-05 ME MEP-2012-131A patent/ME01488B/me unknown
- 2008-06-05 BR BRPI0812889A patent/BRPI0812889A2/pt not_active IP Right Cessation
- 2008-06-05 ES ES11195016.8T patent/ES2531443T3/es active Active
- 2008-06-05 DK DK11195016T patent/DK2444399T3/en active
- 2008-06-05 CA CA2690856A patent/CA2690856C/en not_active Expired - Fee Related
- 2008-06-05 CN CN201210486921.4A patent/CN102977086B/zh not_active Expired - Fee Related
- 2008-06-05 UA UAA200911794A patent/UA99129C2/ru unknown
- 2008-06-05 CN CN2008800191548A patent/CN101679403B/zh not_active Expired - Fee Related
- 2008-06-05 EP EP11195016.8A patent/EP2444399B1/en active Active
- 2008-06-05 PT PT11195016T patent/PT2444399E/pt unknown
- 2008-06-05 EP EP08779348.5A patent/EP2167502B3/en active Active
- 2008-06-05 SI SI200830807T patent/SI2167502T1/sl unknown
- 2008-06-05 JP JP2010511147A patent/JP5416696B2/ja not_active Expired - Fee Related
- 2008-06-05 RS RS20120507A patent/RS52526B2/sr unknown
- 2008-06-05 ES ES08779348T patent/ES2393425T7/es active Active
- 2008-06-05 KR KR1020157026785A patent/KR20150116907A/ko not_active Application Discontinuation
- 2008-06-05 DK DK08779348.5T patent/DK2167502T3/da active
- 2008-06-05 PL PL11195016T patent/PL2444399T3/pl unknown
- 2008-06-05 AR ARP080102401A patent/AR066882A1/es unknown
- 2008-06-05 MX MX2009013078A patent/MX2009013078A/es active IP Right Grant
- 2008-06-05 WO PCT/SE2008/050666 patent/WO2008150233A1/en active Application Filing
- 2008-06-05 PT PT08779348T patent/PT2167502E/pt unknown
- 2008-06-05 PL PL08779348T patent/PL2167502T6/pl unknown
- 2008-06-05 AU AU2008260717A patent/AU2008260717B2/en not_active Ceased
- 2008-06-06 UY UY31124A patent/UY31124A1/es not_active Application Discontinuation
- 2008-06-06 PE PE2008000965A patent/PE20090328A1/es not_active Application Discontinuation
- 2008-06-06 US US12/134,553 patent/US8377939B2/en not_active Expired - Fee Related
- 2008-06-06 CL CL2008001667A patent/CL2008001667A1/es unknown
- 2008-06-07 SA SA08290344A patent/SA08290344B1/ar unknown
-
2009
- 2009-11-16 IL IL202158A patent/IL202158A/en not_active IP Right Cessation
- 2009-11-23 ZA ZA200908285A patent/ZA200908285B/xx unknown
- 2009-12-04 CO CO09139153A patent/CO6251287A2/es not_active Application Discontinuation
-
2010
- 2010-01-06 EC EC2010009856A patent/ECSP109856A/es unknown
- 2010-09-15 HK HK10108742.2A patent/HK1142318A1/xx not_active IP Right Cessation
- 2010-09-15 HK HK12106999.4A patent/HK1166978A1/xx not_active IP Right Cessation
-
2012
- 2012-09-25 RU RU2012141706/04A patent/RU2012141706A/ru not_active Application Discontinuation
- 2012-11-13 HR HRP20120909AT patent/HRP20120909T4/hr unknown
- 2012-11-22 CY CY20121101132T patent/CY1113422T1/el unknown
-
2013
- 2013-11-14 JP JP2013235538A patent/JP5815644B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-24 HR HRP20150210TT patent/HRP20150210T1/hr unknown
- 2015-02-26 CY CY20151100204T patent/CY1116150T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001667A1 (es) | Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño. | |
CL2008001666A1 (es) | Compuestos derivados de 5-([1,2,4]oxadiazol-3-il)-2,3-dihidro-osoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y sus uso en el tratmiento de trastornos neurologicos y psiquiatricos como isquemia cerebral, trauma en la medula espinal, paro cardiaco, demencia, entre otros | |
CL2009000662A1 (es) | Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios. | |
PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
CL2008003591A1 (es) | Compuestos derivados de isoxazolo-piridina sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de trastornos cognitivos y alzheimer, mediado por la union al sitio de fijacion del receptor gaba a alfa 5. | |
EA200971143A1 (ru) | Бензамидные mglur5 позитивные аллостерические модуляторы и способы их получения и применения | |
UY31870A (es) | Receptor metabotrópico de glutamato potenciadores 286 | |
UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
DOP2011000135A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
CU23911B1 (es) | Derivados de amida espiro - ciclícas como moduladores de beta-2-adrenoreceptores útiles para el tratamiento de la bronquitis y el asma | |
CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
AR082600A1 (es) | Polimorfos cristalinos de la sal de besilato de n-(3-(5-fluor-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida, composiciones farmaceuticas que los contienen y uso de los mismos para tratar canceres, enfermedades autoinmunes y oseas, entre otras | |
UY31219A1 (es) | N-[3-(2,6-diclorofenil)-5-alquilo-1,2-oxazol-4-il carbamatos sustituidos y 1-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]ureas sustituidas asi como isomeros, sales farmacéuticas y usos de dichos compuestos | |
ECSP12011983A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
CO6251367A2 (es) | Derivados de 6-amino-5-aril piridina-2il-carboxamida | |
AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
PA8845601A1 (es) | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) | |
AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
CL2009000404A1 (es) | Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras. | |
CR10682A (es) | Compuestos de tiazol pirazolopirimidina | |
PT2139334E (pt) | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos | |
AR076300A1 (es) | Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades. |